The long-term story of launching a plant for the production of drugs based on human blood plasma in the Russian city of Kirov seems to be coming to an end.
As REGNUM news agency was told by the regional government, on 23 March, in Moscow, in the presence of the head of the Kirov region, Igor Vasilyev, and General Director of Rostec state corporation, Sergey Chemezov, signed an agreement on the creation on the premises of Rosplazma factory in Kirov a joint stock company under the name of Kirov Plasma.
The National Immunobiological Company, which is incorporated in Rostec, PJSC Pharmstandard and the Italian pharmaceutical company Kedrion Biopharma founded the enterprise.
The basic design of the facility is planned to be prepared in the third quarter of 2017.
According to the Kirov region’s Governor, Igor Vasilyev, the launch of the plant for the production of blood products in Kirov has a strategic importance not only for the region but also for the country as a whole.